Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy

Mitchell G. Lawrence, Daisuke Obinata, Shahneen Sandhu, Luke A. Selth, Stephen Q. Wong, Laura H. Porter, Natalie Lister, David Pook, Carmel J. Pezaro, David L. Goode, Richard J. Rebello, Ashlee K. Clark, Melissa Papargiris, Jenna Van Gramberg, Adrienne R. Hanson, Patricia Banks, Hong Wang, Birunthi Niranjan, Shivakumar Keerthikumar, Shelley HedwardsAlisee Huglo, Rendong Yang, Christine Henzler, Yingming Li, Fernando Lopez-Campos, Elena Castro, Roxanne Toivanen, Arun Azad, Damien Bolton, Jeremy Goad, Jeremy Grummet, Laurence Harewood, John Kourambas, Nathan Lawrentschuk, Daniel Moon, Declan G. Murphy, Shomik Sengupta, Ross Snow, Heather Thorne, Catherine Mitchell, John Pedersen, David Clouston, Sam Norden, Andrew Ryan, Scott M. Dehm, Wayne D. Tilley, Richard B. Pearson, Ross D. Hannan, Mark Frydenberg, Luc Furic, Renea A. Taylor, Gail P. Risbridger

Research output: Contribution to journalArticlepeer-review

36 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences